These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States. Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691 [TBL] [Abstract][Full Text] [Related]
4. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465 [TBL] [Abstract][Full Text] [Related]
5. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review. Wirdefeldt K; Odin P; Nyholm D CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916 [TBL] [Abstract][Full Text] [Related]
6. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. Fabbri M; Coelho M; Guedes LC; Chendo I; Sousa C; Rosa MM; Abreu D; Costa N; Godinho C; Antonini A; Ferreira JJ Parkinsonism Relat Disord; 2017 Jun; 39():37-43. PubMed ID: 28389156 [TBL] [Abstract][Full Text] [Related]
7. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study]. Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087 [TBL] [Abstract][Full Text] [Related]
8. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study. Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722 [TBL] [Abstract][Full Text] [Related]
10. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Fernandez HH; Odin P Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823 [TBL] [Abstract][Full Text] [Related]
11. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Krack P; Pollak P; Limousin P; Benazzouz A; Deuschl G; Benabid AL Brain; 1999 Jun; 122 ( Pt 6)():1133-46. PubMed ID: 10356065 [TBL] [Abstract][Full Text] [Related]
16. Pain intensity on and off levodopa in patients with Parkinson's disease. Nebe A; Ebersbach G Mov Disord; 2009 Jun; 24(8):1233-7. PubMed ID: 19412949 [TBL] [Abstract][Full Text] [Related]
17. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety]. Timofeeva AA Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138 [TBL] [Abstract][Full Text] [Related]
19. Effect of low-frequency repetitive transcranial magnetic stimulation combined with physical therapy on L-dopa-induced painful off-period dystonia in Parkinson's disease. Kodama M; Kasahara T; Hyodo M; Aono K; Sugaya M; Koyama Y; Hanayama K; Masakado Y Am J Phys Med Rehabil; 2011 Feb; 90(2):150-5. PubMed ID: 20975525 [TBL] [Abstract][Full Text] [Related]
20. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review. Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]